Cysticercosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

4 events
Dec 2025The Impact of Medical TV Drama in Improving Literacy on Neurocysticercosis

Cephas Health Research Initiative Inc, Ibadan, Nigeria — NA

TrialNOT YET RECRUITING
Dec 2024Oxfendazole in Mild Parenchymal Brain Cysticercosis

Universidad Peruana Cayetano Heredia — PHASE2, PHASE3

TrialNOT YET RECRUITING
Jun 2024Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

R-Evolution Worldwide S.r.l. Impresa Sociale — PHASE4

TrialNOT YET RECRUITING
Oct 1985Natural History of Treated Neurocysticercosis and Long-Term Outcomes

National Institute of Allergy and Infectious Diseases (NIAID)

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

1

Copay cards

Copay Assistance1

ALBENZA

Impax Laboratories

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Albenza

(Albendazole)Orphan drugstandard

Impax Laboratories, LLC

Anthelmintic [EPC]

12.1 Mechanism of Action ALBENZA (albendazole) is a synthetic, antihelminthic drug of the class benzimidazole [ see Clinical Pharmacology ( 12.4 ) ].

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

1 active trial
1Unknown
1Total recruiting
Search clinical trials for Cysticercosis

Recent News & Research

No recent news articles indexed yet for Cysticercosis.
Search PubMed for Cysticercosis

Browse all Cysticercosis news →

Specialist Network

Top 6 by expertise

View all Cysticercosis specialists →

Quick Actions